Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis

Mohammad Hashemi; Gholamreza Bahari; Jarosław Markowski; Andrzej Małecki; Marek J Łos; Saeid Ghavami

doi:10.18632/oncotarget.25324

Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis

Oncotarget. 2018 May 15;9(37):24857-24868. doi: 10.18632/oncotarget.25324.

Authors

Mohammad Hashemi^{1

2}, Gholamreza Bahari², Jarosław Markowski³, Andrzej Małecki⁴, Marek J Łos^{5

6}, Saeid Ghavami^{7

8}

Affiliations

¹ Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
² Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
³ ENT Department, School of Medicine, Medical University of Silesia in Katowice, Katowice, Poland.
⁴ Faculty of Physiotherapy, The Jerzy Kukuczka Academy of Physical Education in Katowice, Katowice, Poland.
⁵ Department of Molecular Biology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, Katowice, Poland.
⁶ Centre de Biophysique Moléculaire, CNRS, Rue Charles Sadron, Orleans, France.
⁷ Department of Human Anatomy and Cell Science, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
⁸ Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract

This study was designed to evaluate the relationship between Programmed cell death protein 6 (PDCD6) polymorphisms and cancer susceptibility. The online databases were searched for relevant case-control studies published up to November 2017. Review Manage (RevMan) 5.3 was used to conduct the statistical analysis. The pooled odds ratio (OR) with its 95% confidence interval (CI) was employed to calculate the strength of association. Overall, our results indicate that PDCD6 rs3756712 T>G polymorphism was significantly associated with decreased risk of cancer under codominant (OR = 0.82, 95%CI = 0.70-0.96, p = 0.01, TG vs TT; OR = 0.53, 95%CI = 0.39-0.72, p < 0.0001, GG vs TT), dominant (OR = 0.76, 95%CI = 0.66-0.89, p = 0.0004, TG+GG vs TT), recessive (OR = 0.57, 95%CI = 0.43-0.78, p = 0.0003, GG vs TT+TG), and allele (OR = 0.76, 95%CI = 0.67-0.86, p < 0.00001, G vs T) genetic model. The finding did not support an association between rs4957014 T>G polymorphism of PDCD6, and different cancers risk.

Keywords: PDCD6; cancer; endometrial cancer; meta-analysis; risk.

Publication types

Review